CAPA – Page 408 – Pharma.Tips

Cross-contamination detected during inspection prep – manufacturing vs material root cause

Detection of Cross-contamination During Inspection Preparation: Investigating Manufacturing vs Material Root Causes Cross-contamination during inspection preparation can have serious implications for pharmaceutical manufacturing quality and compliance. This situation not only…

Dissolution failure during encapsulation – regulatory inspection finding risk

Dissolution Challenges During Encapsulation: Navigating Regulatory Inspection Risks Dissolution failures during the encapsulation process can trigger significant challenges for pharmaceutical manufacturers, leading to deviations, out-of-specification (OOS) results, and potential regulatory…

Capsule locking failure during inspection prep – manufacturing vs material root cause

Managing Capsule Locking Failures: An Investigation into Manufacturing and Material Root Causes In the pharmaceutical industry, maintaining product integrity is crucial, particularly during the inspection preparation phase of capsule manufacturing.…

Color variation observed during inspection prep – CAPA inadequacy explained

Investigating Color Variation Observed During Inspection Preparation: Addressing CAPA Inadequacies Color variation in pharmaceutical capsules during inspection preparation is more than an aesthetic concern; it often flags potential manufacturing defects…

Capsule shell brittleness after humidity excursion – CAPA inadequacy explained

Understanding Capsule Shell Brittleness after Humidity Excursions: A Detailed Investigation The integrity of capsule shells is paramount in pharmaceutical manufacturing, and incidents of brittleness after humidity excursions can significantly impact…

Capsule fill weight variability after humidity excursion – manufacturing vs material root cause

Investigation of Capsule Fill Weight Variability Following Humidity Excursion in Manufacturing Processes In pharmaceutical manufacturing, maintaining stringent control over environmental conditions is paramount to ensure product quality and compliance. One…

Tablet chipping complaint during compression – process vs formulation assessment

Addressing Tablet Chipping Complaints During Compression: A Comprehensive Investigation Framework Tablet chipping during the compression process is a critical manufacturing defect that can compromise product integrity and quality. Addressing this…

Disintegration time failure during campaign changeover – root cause analysis breakdown

Analysis of Disintegration Time Failures During Campaign Changeovers In pharmaceutical manufacturing, particularly during the production of tablets, disintegration time is a critical quality parameter. A failure in achieving the specified…

Disintegration time failure during compression – CAPA failure identified

Addressing Disintegration Time Failures During Compression: A Root Cause Investigation Guide In the realm of pharmaceutical manufacturing, particularly in tablet formulation, discrepancies in disintegration time during compression can lead to…

Friability failure after tooling change – FDA inspection observation risk

Managing Friability Failures Following Tooling Changes to Mitigate FDA Inspection Risks Friability failures in tablet manufacturing can pose significant risks to product quality and regulatory compliance, often triggering investigations and…

Tablet chipping complaint during high-speed runs – CAPA failure identified

Investigating Tablet Chipping Complaints During High-Speed Production Runs Tablet chipping during high-speed runs presents significant challenges in pharmaceutical manufacturing, leading to product integrity issues and quality complaints. As a manufacturing…

Black specks detected after tooling change – CAPA failure identified

Investigating Black Specks Detected Following Tooling Changes in Tablet Manufacturing In the competitive landscape of pharmaceutical manufacturing, maintaining product integrity is paramount. Instances of contamination or defects, such as black…